US2020018750A1PendingUtilityA1

Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis

51
Assignee: SARWAL MINNIEPriority: Apr 4, 2014Filed: Apr 24, 2019Published: Jan 16, 2020
Est. expiryApr 4, 2034(~7.7 yrs left)· nominal 20-yr term from priority
Inventors:Minnie M. Sarwal
C07K 2317/34C07K 16/2878C07K 2317/21G01N 33/564
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided herein are methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis and oilier proteinuric renal diseases such as native FSGS, minimal change disease, glomerular nephritis, membrano-proliferative glomerular nephritis (membranous), or IgA glomerular nephritis (membranous).

Claims

exact text as granted — not AI-modified
1 .  1 - 57 . (canceled) 
     
     
         58 . A method of treating recurrent focal segmental glomerulosclerosis (rFSGS) comprising administering a blocking antibody that binds to CD40 in an individual in need thereof. 
     
     
         59 . The method of  claim 58 , wherein the blocking antibody blocks binding of an autoantibody to epitopes of CD40 comprising the amino acid sequence(s) NSQCC and/or ESEF. 
     
     
         60 . The method of  claim 58 , wherein the method is carried out after the individual has undergone kidney transplantation. 
     
     
         61 . The method of  claim 58 , further comprising treating the individual with plasmapheresis. 
     
     
         62 . The method of  claim 58 , further comprising treating the individual with antibody immunoadsorption. 
     
     
         63 . The method of  claim 58 , further comprising treating the individual with rituximab.

Join the waitlist — get patent alerts

Track US2020018750A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.